BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Aulos Bioscience\, Inc. readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of studies Aulos Bioscience\, Inc.'s drugs r
 un\, from ClinicalTrials.gov estimates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT05267626-2364@assetmemo.bio
DTSTAMP:20261121T005810Z
DTSTART;VALUE=DATE:20270228
DTEND;VALUE=DATE:20270301
SUMMARY:Imneskibart: Phase 1/2 readout est. (NCT05267626)
DESCRIPTION:Imneskibart\, phase 1/2\, Non-Small Cell Lung Cancer.\nStudy: S
 tudy of AU-007\, A Monoclonal Antibody That Binds to IL-2 and Inhibits IL-
 2Rα Binding\, in Patients With Unresectable Locally Advanced or Metastati
 c Cancer\nEstimated primary completion: 28 February 2027. This is a Clinic
 alTrials.gov estimate\, not a confirmed readout date\, and it can move.\nD
 rug page: https://assetmemo.bio/drug/imneskibart#upcoming-events\nRegistry
  record: https://clinicaltrials.gov/study/NCT05267626
URL:https://assetmemo.bio/drug/imneskibart#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
